Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison in US Adolescents of the Safety and Immunogenicity of Two Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccines: ADACEL and BOOSTRIX

Trial Profile

Comparison in US Adolescents of the Safety and Immunogenicity of Two Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccines: ADACEL and BOOSTRIX

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Oct 2012

At a glance

  • Drugs DTaP vaccine (Primary)
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 02 Feb 2010 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 02 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Apr 2008 The expected completion date for this trial is now 1 Oct 2008 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top